HRP20191240T1 - Terapija matičnim stanicama kod patologija endometrija - Google Patents

Terapija matičnim stanicama kod patologija endometrija Download PDF

Info

Publication number
HRP20191240T1
HRP20191240T1 HRP20191240T HRP20191240T1 HR P20191240 T1 HRP20191240 T1 HR P20191240T1 HR P20191240 T HRP20191240 T HR P20191240T HR P20191240 T1 HRP20191240 T1 HR P20191240T1
Authority
HR
Croatia
Prior art keywords
bmdscs
isolated
subject
use according
administered
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Carlos Simón
Javier Santamaria
Antonio Pellicer
Irene Cervello
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of HRP20191240T1 publication Critical patent/HRP20191240T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
HRP20191240 2014-06-17 2015-06-05 Terapija matičnim stanicama kod patologija endometrija HRP20191240T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17
EP15781411.2A EP3158057B1 (en) 2014-06-17 2015-06-05 Stem cell therapy in endometrial pathologies
PCT/IB2015/001715 WO2015193737A1 (en) 2014-06-17 2015-06-05 Stem cell therapy in endometrial pathologies

Publications (1)

Publication Number Publication Date
HRP20191240T1 true HRP20191240T1 (hr) 2019-11-01

Family

ID=54329860

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20191240 HRP20191240T1 (hr) 2014-06-17 2015-06-05 Terapija matičnim stanicama kod patologija endometrija
HRP20220419TT HRP20220419T1 (hr) 2014-06-17 2015-06-05 Terapija matičnim stanicama kod patologija endometrija
HRP20240798TT HRP20240798T1 (hr) 2014-06-17 2015-06-05 Terapija matičnim stanicama kod patologija endometrija

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20220419TT HRP20220419T1 (hr) 2014-06-17 2015-06-05 Terapija matičnim stanicama kod patologija endometrija
HRP20240798TT HRP20240798T1 (hr) 2014-06-17 2015-06-05 Terapija matičnim stanicama kod patologija endometrija

Country Status (22)

Country Link
US (1) US11129851B2 (enExample)
EP (3) EP4012023B1 (enExample)
JP (2) JP6920062B2 (enExample)
CN (2) CN116747241A (enExample)
AU (1) AU2015275798B2 (enExample)
BR (1) BR112016029558A2 (enExample)
CA (1) CA2952559C (enExample)
CY (2) CY1122615T1 (enExample)
DK (2) DK3158057T3 (enExample)
ES (3) ES2983444T3 (enExample)
HR (3) HRP20191240T1 (enExample)
HU (3) HUE058328T2 (enExample)
LT (2) LT3569697T (enExample)
MX (1) MX377300B (enExample)
PL (3) PL3569697T3 (enExample)
PT (2) PT3569697T (enExample)
RS (3) RS65719B1 (enExample)
RU (1) RU2725006C2 (enExample)
SI (2) SI3569697T1 (enExample)
SM (3) SMT202400270T1 (enExample)
TR (1) TR201910410T4 (enExample)
WO (1) WO2015193737A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
CA2888122A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
BR112016029558A2 (pt) 2014-06-17 2017-08-22 Igenomix S L terapia de células-tronco em patologias endometriais
AU2017281631B2 (en) * 2016-06-23 2023-06-15 Tithon Biotech, Inc. Cells expressing parathyroid hormone 1 receptor and uses thereof
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240922A (en) 1989-05-05 1993-08-31 Northern Sydney Area Health Service Fertility enhancement
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
AU2001240096A1 (en) 2000-03-08 2001-09-17 Rebecca L. Dubowy Methods of diagnosing and monitoring endometrial glandular development
JP2004504275A (ja) 2000-05-24 2004-02-12 シエーリング　アクチエンゲゼルシャフト フィブリン−１の医薬用途
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
EP1511863A4 (en) 2002-05-14 2006-12-27 Univ Leland Stanford Junior ENDOMETRIAL GENES FOR THE DETECTION OF ENDOMETRIAL DISORDERS
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ATE338763T1 (de) 2002-08-02 2006-09-15 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10361928A1 (de) 2002-12-21 2004-07-01 Universität Leipzig Verfahren und Mittel zur Bestimmung von bestimmten Zuständen bzw. Veränderungen im Uterusepithel und im Epithel anderer Organe
EP1660228A1 (en) 2003-08-21 2006-05-31 PamGene B.V. Microarray support for bioprobe synthesis
EP1670902A4 (en) 2003-09-08 2008-05-07 Univ Texas METHOD AND COMPOSITION FOR ENHANCING i IN VITRO /i EMBRYO DEVELOPMENT BY SUPPLEMENTING CULTURE MEDIUM WITH PROSTAGLANDIN OR A PROSTAGLANDIN ANALOG
JP2007504807A (ja) 2003-09-08 2007-03-08 ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 培養培地にプロスタグランジン又はプロスタグランジン類似物を補足することによってインビトロ胚発生を高めるための方法及び組成
DE602004028513D1 (de) 2003-12-23 2010-09-16 Mount Sinai Hospital Corp Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
JP2008501035A (ja) 2004-05-28 2008-01-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 妊孕性関連障害の治療におけるｉｌ−１７の使用
US20090111140A1 (en) * 2006-03-31 2009-04-30 Koninklijke Philips Electronics N.V. Systems and methods for cell measurement utilizing ultrashort t2*
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
PT2768976T (pt) 2011-10-21 2018-04-05 Inst Nat Sante Rech Med Métodos para avaliar a receptividade endométrica de uma paciente após hiperestimulação ovárica controlada
US9423402B2 (en) 2011-11-30 2016-08-23 Singapore Health Services Pte. Ltd. GM1 ganglioside to annexin V microparticle polypeptide ratio for biological monitoring
SG11201407667UA (en) 2012-06-27 2015-02-27 Hoffmann La Roche MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
RU2515475C1 (ru) 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
CA2943284A1 (en) 2014-03-21 2015-11-05 Igenomix S.L. Early detection of preeclampsia
BR112016029558A2 (pt) 2014-06-17 2017-08-22 Igenomix S L terapia de células-tronco em patologias endometriais

Also Published As

Publication number Publication date
LT3569697T (lt) 2022-04-25
ES2983444T3 (es) 2024-10-23
EP4012023C0 (en) 2024-05-15
SMT202400270T1 (it) 2024-07-09
DK3569697T3 (da) 2022-04-04
PL3158057T3 (pl) 2020-05-18
JP6920062B2 (ja) 2021-08-18
RU2017101147A (ru) 2018-07-17
PT3158057T (pt) 2019-07-19
PT3569697T (pt) 2022-05-02
WO2015193737A1 (en) 2015-12-23
JP2020138984A (ja) 2020-09-03
LT3158057T (lt) 2019-09-25
EP4012023A1 (en) 2022-06-15
SMT201900400T1 (it) 2019-09-09
MX2016016756A (es) 2017-11-02
RU2725006C2 (ru) 2020-06-29
US20170128492A1 (en) 2017-05-11
DK3158057T3 (da) 2019-07-29
MX377300B (es) 2025-03-07
RS59210B1 (sr) 2019-10-31
CN107073040A (zh) 2017-08-18
EP3569697B8 (en) 2022-04-27
EP3569697B1 (en) 2022-01-05
EP4012023B1 (en) 2024-05-15
CY1125938T1 (el) 2024-02-16
SMT202200155T1 (it) 2022-05-12
EP3158057A1 (en) 2017-04-26
RU2017101147A3 (enExample) 2019-02-06
EP3569697A1 (en) 2019-11-20
BR112016029558A2 (pt) 2017-08-22
CN116747241A (zh) 2023-09-15
ES2736117T3 (es) 2019-12-26
RS63093B1 (sr) 2022-04-29
SI3158057T1 (sl) 2019-10-30
EP3158057B1 (en) 2019-04-17
RS65719B1 (sr) 2024-08-30
AU2015275798B2 (en) 2021-03-25
ES2910306T3 (es) 2022-05-12
HUE058328T2 (hu) 2022-07-28
HRP20240798T1 (hr) 2024-09-27
HRP20220419T1 (hr) 2022-05-27
TR201910410T4 (tr) 2019-08-21
CY1122615T1 (el) 2021-03-12
CA2952559C (en) 2023-01-24
PL4012023T3 (pl) 2024-09-02
US11129851B2 (en) 2021-09-28
CA2952559A1 (en) 2015-12-23
JP2017522288A (ja) 2017-08-10
SI3569697T1 (sl) 2022-05-31
PL3569697T3 (pl) 2022-07-04
HUE067463T2 (hu) 2024-10-28
AU2015275798A1 (en) 2017-02-02
HUE044823T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
HRP20240798T1 (hr) Terapija matičnim stanicama kod patologija endometrija
MX2025009223A (es) Agentes de union a clec9a y su uso
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
MX2016010683A (es) Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
MX2019010907A (es) Agonistas del receptor x farnesoide, y usos de los mismos.
CR20190247A (es) Métodos para el tratamiento de la atrofia muscular y enfermedad ósea con el uso de proteínas trap híbridas novedosas del ligando actriib
JP2017522288A5 (enExample)
CO6640274A2 (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
EP3238745A4 (en) CELL TODINDUCATING AGENT, CYTOSTATIC AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ILLNESSES THROUGH ABNORMAL CELL GROWTH
IL283469A (en) Inhalable preparations for use in the treatment of lung diseases
BR112017005713A2 (pt) composto da fórmula (i), método de mobilização das células-tronco hematopoiéticas (hsc) e células progenitoras endoteliais (epc) na circulação periférica, método de tratamento de lesão tecidual, câncer, doença inflamatória ou doença autoimune, e composição farmacêutica
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
PE20151746A1 (es) Compuestos biciclicos
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
MX2017013795A (es) Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios.
CR20170470A (es) Tratamiento de pacientes con diabetes mellitus tipo 2